A U.S. appeals court has blocked Novartis AG from selling its knockoff version of an Amgen Inc. cancer supportive-care drug in the U.S. until the court resolves a legal fight between the rivals.

The U.S. Court of Appeals for the Federal Circuit in Washington on May 5 granted Amgen’s request for an injunction blocking Novartis’s Zarxio from the U.S. market until the court resolves Amgen’s appeal of a lower-court ruling that gave the green light to Zarxio’s market entry. 

The new order is expected to keep Zarxio off the U.S. market at least until June 3, when oral arguments are scheduled, though resolution of the case could take longer.

For more details, go to: http://www.wsj.com/articles/court-blocks-novartis-copy-of-amgen-cancer-care-drug-1431018258